Hong Kong To Limit Tests, Antivirals To Those At High H1N1 Flu Risk
This article was originally published in PharmAsia News
Executive SummaryHong Kong authorities have decided to limit tests and antiviral treatment for the H1N1 flu to patients considered at high risk for the disease. Clinicians are to determine those who should be treated, the Hong Kong Hospital Authority said. The tests and treatment are to be given to patients showing symptoms if they are under six years of age, pregnant or have chronic diseases, or have a persistent fever two days after symptomatic treatment. (Click here for more
You may also be interested in...
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.